Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from ...
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.
Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth ...
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review ...
As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting ...
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per ...
Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results